

Biographical Sketch

Provide the following information for each individual included in the Research & Related Senior/Key Person Profile (Expanded) Form.

NAME MARILYN K. GLASSBERG	POSITION TITLE PROFESSOR
---------------------------	--------------------------

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training).

INSTITUTION AND LOCATION	DEGREE (IF APPLICABLE)	YEAR(S)	FIELD OF STUDY
Wellesley College, Wellesley, MA University of Miami Miller School of Medicine, Miami, FL	B.A. with honors M.D.	1980 1985	Biology/Psychology Medicine

RESEARCH AND PROFESSIONAL EXPERIENCE:

Positions and Employment

1980-1981	Research Assistant, Depts. of Surgery and Physiology, Drs. Judah Folkman and Bruce Zetter, Division of Surgical Research, Children's Hospital, Harvard Medical School, Boston, MA
7/85-6/88	University of Miami School of Medicine, Jackson Memorial Hospital, Miami, FL, Internal Medicine, PGY-1, PGY-2, PGY-3
7/88-6/91	Pulmonary Fellow, Pulmonary Division, Department of Medicine, University of Miami School of Medicine. ALAF Fellow 1989-1990. Dr. Una Ryan
7/91-6/92	Pulmonary Research Fellow, Pulmonary Division and Biochemistry and Molecular Biology, Department University of Miami School of Medicine. Dr. David Puett
1992-1998	Assistant Professor of Clinical Medicine, University of Miami School of Medicine
1998-2005	Assistant Professor of Medicine (Tenure-track), UMMSM
2005-2012	Associate Professor of Medicine, University of Miami Miller School of Medicine
2009-2012	Associate Professor of Surgery, University of Miami Miller School of Medicine
2005-present	Director, Rare and Interstitial Lung Disease Program
2012-present	Professor of Medicine and Surgery, UMMSM
2013-present	Director, Pulmonary Division of Interdisciplinary Stem Cell Institute
2014-present	Vice-Chairman of Medicine for Innovation and Diversity, Department of Medicine, University of Miami Miller School of Medicine (UMMSM)

RESEARCH AND PROFESSIONAL EXPERIENCE (CONTINUED).

Other Experience and Professional Memberships

1982 Member, Sigma Xi
1988- Member, American Thoracic Society
1988 Member, American College of Physicians
1995-pres. Reviewer, American Review of Respiratory Cell and Molecular Biology
1995-pres. Reviewer, American Journal of Respiratory and Critical Care Medicine
1995-pres. Reviewer, Chest
1997 Fellow, American College of Chest Physicians
1991-pres. Reviewer, American Journal of Physiology: Lung Cell and Molecular Physiology
2005 Ad Hoc Reviewer, COPD RFA and R-13 (NHLBI)
2005-2007 Co-Chair of American College of Chest Physicians (ACCP) National Task Force on Women & Girls, Tobacco & Lung Cancer
2006 Grant Reviewer, Office of Orphan Drug Development, FDA
2007-2010 President, Southeast Thoracic Association
2008 Special Emphasis Study Section R-13 (NHLBI)
2009 Asthma Net Study Section (NHLBI)
2009 LRP study section (NIH/NHLBI)
2010 American Lung Association CME/CE Committee
2010 PAR-09-185 Translational Programs in Lung Disease Study Section (NHLBI)
2010-2014 Membership Committee, American Thoracic Society
2011 Steering Committee, ASCEND trial for Pirfenidone in Idiopathic pulmonary fibrosis
2011 NIH Board of Scientific Counselors Intramural Scientific Review: Dr. Joel Moss
2013 FDA Orphan Office Pulmonary Research Grant Program (OOPD), Review panel
2014-present Editorial Board, American Journal of Respiratory and Critical Care Medicine
2015-2016 Nominating Committee Chair, American Thoracic Society Clinical Problems Assembly
2016 International Chair, DSMB, Genentech/Roche Combined therapy for IPF Phase 3 trial
2016 FDA OOPD, Review panel

Honors

1989 Young Investigator Award, International Society for Applied Cardiovascular Biology
1993 Young Investigator Award, Third International Conference on Endothelin
1995 Servier Young Investigator Award, Fourth International Conference on Endothelin
2002 University of Miami Women's Medical Association Teaching Award
2003 National Library of Medicine Award
2004 University of Miami School of Medicine Medical Student Teaching Award
2006-2007 University of Miami School of Medicine Medical Student Teaching Award
2009-2011 University of Miami School of Medicine, Faculty Senate
2010 Invited presentation, NIH Office of Research on Women's Health 20th Anniversary
2011 Invited presentation, CHEST plenary lecture on LAM, Honolulu, HI
2013 Chairperson, Smoking: hazards for elementary children, ACCP Outreach, Miami, FL
2014 Co-chairperson, "Tomorrow never comes: translational approaches to IPF"-ATS Denver
2015 Invited presentation, "A new era in IPF: using cell-based therapies in chronic lung disease," Eastern Pulmonary Conference, Palm Beach, FL.
2015 Dines Named Visiting Professor, Mayo Clinic, Rochester, MN
2016 Invited presentation, "Advancing cell-based therapies to patients with IPF," Vatican Stem Cell Conference, Rome, Italy
2016 Co-Chairperson, "What, when, where: clearing the air on stem cell therapies in pulmonary diseases," American Thoracic Society, San Francisco, CA

RESEARCH AND PROFESSIONAL EXPERIENCE (CONTINUED). PAGE LIMITATIONS APPLY. DO NOT EXCEED 5 PAGES FOR THE ENTIRE BIOGRAPHICAL SKETCH PER INDIVIDUAL.

1. **Glassberg MK**, Hare JM, Toonkel RL, Matthay MA. *Am J Respir Crit Care Med*. 2013 Jul 15;188(2):253-4. doi: 10.1164/rccm.201302-0244LE. [Reply: idiopathic pulmonary fibrosis: a degenerative disease requiring a regenerative approach.](#)
2. Doyle TJ, Lee JS, Dellaripa PF, Lederer JA, Matteson EL, Fischer A, Ascherman DP, **Glassberg MK**, Ryu JH, Danoff SK, Brown KK, Collard HR, Rosas IO. *Chest*. 2014 Mar 1;145(3):454-63. doi: 10.1378/chest.13-2408. [A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.](#)
3. **Glassberg MK**. Targeting the Pathophysiology of Idiopathic Pulmonary Fibrosis: Inhibiting Fibrogenetic Processes. <http://www.quintilesmeded.com/inhibiting-IPF>. November 2013.
4. **Glassberg MK**. Current and Investigational Treatment Options for IPF. Chapter 4 [http://www. Project knowledge.com.@Point of Care360: Idiopathic Pulmonary Fibrosis Edition](http://www.Projectknowledge.com.@PointofCare360:IdiopathicPulmonaryFibrosisEdition). August 2013
5. Noble PW, Bradford WZ, Fagan EA, Glaspole I, **Glassberg MK**, Lancaster L, Kardarazke D, Lederer D, Leff, JA, Nathan SD, Pereira C, Sahn SA, Swigris JJ, and King TE. *Am J Resp Crit Care Med* 2013 Dec. [Improving clinical trial efficiency in Idiopathic Pulmonary Fibrosis: Multivariate Analysis to Support the design of the ASCEND study.](#)
6. Toonkel RL, Hare JM, Matthay MA, Glassberg MK. *Am J Respir Crit Care Med*. 2013 Jul 15; 188(2):133-40. doi: 10.1164/rccm.201207-1204PP. [Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.](#)
7. **Glassberg MK**. *Am J Respir Crit Care Med*. 2013 Aug 1; 188(3):397-8. doi: 10.1164/rccm.201210-1912LE. [To be or not to be a neoplasm: what is lymphangioliomyomatosis? Are we calling it what it really is?](#)
8. **Glassberg MK**, Rosen G, Staton G. Proactive and comprehensive management of patients with IPF <https://www.ipfrally.com/managing-the-ipf-patient>. April 2014.
9. **Glassberg MK**, Choi R, Manzoli V, Shahzeidi S, Rauschkolb P, Voswinckel R, Aliniaze M, Xia X, Elliot SJ. *Endocrinology*. 2014 Feb; 155(2):441-8. doi: 10.1210/en.2013-1345. Epub 2013 Nov 25. [17 \$\beta\$ -estradiol replacement reverses age-related lung disease in estrogen-deficient C57BL/6J mice.](#)
10. **Glassberg MK**, Toonkel RL. *Respirology*. 2014 Oct; 19(7):950-1. doi: 10.1111/resp.12364. Epub 2014 Aug 14. [Moving stem cell therapy to patients with idiopathic pulmonary fibrosis.](#)
11. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, **Glassberg MK**, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. *N Engl J Med*. 2014 May 29; 370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: *N Engl J Med*. 2014 Sep 18; 371(12):1172. [A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.](#)
12. Miller SA, **Glassberg MK**, Ascherman DP. *Rheum Dis Clin North Am*. 2015 May;41(2):249-262. doi: 10.1016/j.rdc.2014.12.006. Epub 2015 Feb 27. Review. [Pulmonary Complications of Inflammatory Myopathy.](#)
13. Catanuto P, Tashiro J, Rick FG, Sanchez P, Solorzano CC, **Glassberg MK**, Block NL, Lew JI, Elliot SJ, Schally AV. *Horm Cancer*. 2015 Mar 10. [Epub ahead of print] [Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone \(pGHRH-R\) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.](#)
14. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, **Glassberg MK**, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. *Chest*. 2015 Apr 9. doi: 10.1378/chest.14-2817. [Sensitivity Analyses of the Change in Forced Vital Capacity in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.](#)

15. Tashiro J and Elliot SJ * (equal authorship) Gerth DJ, Xia X, Pereira-Simon S, Choi R, Catanuto P, Shahzeidi S, Toonkel R, Shah R, El Salem F, **Glassberg MK**. [Therapeutic Benefits of Young, But Not Old, Adipose-Derived Mesenchymal Stem Cells in a Chronic Mouse Model of Bleomycin-Induced Pulmonary Fibrosis](#). *Transl Res. Dec*; 166(6):554-67, 2015.
16. Rubio GA, Elliot SJ, **Glassberg MK**. [What should be chronic? The animal, the model, or both? Stem Cells Transl Med](#). May; 5(5):703, 2016.
17. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, **Glassberg MK**, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. [Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis](#). *Thorax*. May;71(5):429-35, 2016.
18. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, **Glassberg MK**, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. [Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials](#). *BMJ Open Respir Res*. Jan 12;3(1), 2016.
19. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, **Glassberg MK**, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. [Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials](#). *Eur Respir J*. Jan; 47(1):243-53, 2016

Representative earlier publications pertinent to this application:

1. **Glassberg MK**, Elliot SJ, Fritz J, Catanuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M. *J Clin Endocrinol Metab*. 2008 May; 93(5):1625-33. [Activation of the estrogen receptor contributes to the progression of pulmonary lymphangiomyomatosis via matrix metalloproteinase-induced cell invasiveness](#).
2. Kassira N, **Glassberg MK**, Jones C, Pincus DJ, Elliot SJ, Fritz JR, Karl M, Thaller S. *Ann Plast Surg*. 2009 Sep;63(3):318-22. doi: 10.1097/SAP.0b013e318184ac15. [Estrogen deficiency and tobacco smoke promote MMP-13 activation in skin of aging B6 mice](#).
3. Jackson RM, **Glassberg MK**, Ramos CF, Bejarano PA, Butrous G, Gómez-Marin O. *Lung Apr* 2010, 188 (2): 115-123, 2010. [Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis](#).
4. Noble PW, Albera C, Bradford WZ, Costabel U, **Glassberg MK**, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. *Lancet*. 2011 May 21; 377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. [Pirfenidone in patients with idiopathic pulmonary fibrosis \(CAPACITY\): two randomised trials](#).
5. Jackson RM, **Glassberg MK**, Ramos CF, Bejarano PA, Butrous G, Gómez-Marin O. *Lung Apr* 2010, 188 (2): 115-123, 2010. [Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis](#).